论文部分内容阅读
英国批准普伐他汀的新适应症布迈－施贵宝（ＢｒｉｓｔｏｌＭｙｅｒｓＳｑｕｉｂｂ）公司的降血脂药普伐他汀（Ｐｒａｖａｓｔａｔｉｎ）在英国获准用于新的适应症：对于有心脏病发作史并确诊为动脉粥样硬化的患者，减慢其动脉粥样硬化的发展和减少临床心脏病的发作。该公...
UK Approves Pravastatin for New Indications Pravastatin, a lipid-lowering drug from Bristol Myers Squibb, is licensed for new indications in the UK: For patients who have a history of heart attacks and are diagnosed with atherosclerosis Of patients, slowing its development of atherosclerosis and reducing the incidence of clinical heart disease. The public ...